FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.